{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:54:06Z","timestamp":1785873246535,"version":"3.56.0"},"reference-count":23,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":8859,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1993,10]]},"abstract":"<jats:p>The effectiveness of ritanserin, a selective 5-HT<jats:sub>2<\/jats:sub>and 5-HT<jats:sub>1c<\/jats:sub>antagonist, in reducing negative symptoms in schizophrenia was investigated in a double-blind, placebo-controlled trial. Trial treatment was added to a stable neuroleptic treatment in 33 schizophrenic patients with predominantly negative symptoms. Ritanserin reduced the negative symptoms, as measured with the SANS. The main reduction was for the items facial expression, global affective flattening, and relationships with friends and peers. Also a reduction in total BPRS score was found, which approached statistical significance. Significant reductions were observed for the BPRS items emotional withdrawal and depressive mood. Ritanserin or other drugs blocking 5-HT<jats:sub>2<\/jats:sub>and\/or 5-HT<jats:sub>1c<\/jats:sub>receptors could be important in reducing specific symptoms in schizophrenic patients.<\/jats:p>","DOI":"10.1192\/bjp.163.4.451","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T05:21:28Z","timestamp":1224048088000},"page":"451-455","source":"Crossref","is-referenced-by-count":124,"title":["Ritanserin, a Selective 5-HT<sub>2\/1C<\/sub>Antagonist, and Negative Symptoms in Schizophrenia"],"prefix":"10.1192","volume":"163","author":[{"given":"S. J.","family":"Duinkerke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Botter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A. I.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A. M.","family":"Van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Van Haaften","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Boom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. M.","family":"Van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. L. S. M.","family":"Busard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000033833_ref21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/ajp.138.4.460","article-title":"Dopamine receptors, neuroleptics and schizophrenia","volume":"138","author":"Snyder","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000033833_ref14","unstructured":"Niemegeers C. J. E. & Awouters F. (1985) In Vivo Study of the Possible Inhibition and Induction of Microsomal Enzymes by Ritanserin (R 55 667), a Serotonin-S2 Antagonist. Beerse, Belgium: Janssen Pharmaceutica, preclinical research report on R 55 667\/23."},{"key":"S0007125000033833_ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430080124"},{"key":"S0007125000033833_ref12","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.2.130"},{"key":"S0007125000033833_ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431683"},{"key":"S0007125000033833_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90193-9"},{"key":"S0007125000033833_ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.3.928"},{"key":"S0007125000033833_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"S0007125000033833_ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199012000-00003"},{"key":"S0007125000033833_ref19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1145194"},{"key":"S0007125000033833_ref23","first-page":"107","article-title":"Ritanserin in schizophrenic patients","volume":"31","author":"Vinar","year":"1989","journal-title":"Activitas Nervosa Superior"},{"key":"S0007125000033833_ref15","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"S0007125000033833_ref20","first-page":"9","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"S0007125000033833_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/1.11.61"},{"key":"S0007125000033833_ref4","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.3.317"},{"key":"S0007125000033833_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-009-1912-9_40"},{"key":"S0007125000033833_ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6207.66"},{"key":"S0007125000033833_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00433802"},{"key":"S0007125000033833_ref13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","article-title":"Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin S2-antagonist","volume":"27","author":"Leysen","year":"1985","journal-title":"Molecular Pharmacology"},{"key":"S0007125000033833_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90299-4"},{"key":"S0007125000033833_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb05533.x"},{"key":"S0007125000033833_ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470030309"},{"key":"S0007125000033833_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290070020005"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000033833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:21:28Z","timestamp":1738437688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000033833\/type\/journal_article"}},"subtitle":["A Placebo-Controlled Double-Blind Trial"],"short-title":[],"issued":{"date-parts":[[1993,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,10]]}},"alternative-id":["S0007125000033833"],"URL":"https:\/\/doi.org\/10.1192\/bjp.163.4.451","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,10]]}}}